泛素连接酶
T细胞受体
Jurkat细胞
嵌合抗原受体
CD3型
生物
细胞生物学
融合蛋白
分子生物学
受体
T细胞
泛素
下调和上调
跨膜蛋白
跨膜结构域
抗原
基因
生物化学
遗传学
CD8型
重组DNA
免疫系统
作者
Michael J. Harris,Hao Chen,Tianyu Cai,Yuting Yi,Qiaowen Deng,Yi Yao,Tianle Lan,Yanfeng Guo,Xiufang Xu,X. Wen,Joshua E. McGee,Daniella Tatang,James Brock,Feng Shi,Li Zhou
标识
DOI:10.1021/acssynbio.1c00397
摘要
Receptor downregulation is instrumental for many therapeutic interventions. Receptor knockout through gene-editing technologies is efficient but can introduce off-target mutations and chromothripsis. Regulation of gene expression at the protein level is a promising alternative. Here, we present results showing the targeted T cell antigen receptor (TCR) degradation using chimeric E3 fusion proteins that we call Receptor Targeting Chimeras (ReceptorTAC). We show that TCR degradation is dependent on enzymatically active, membrane-anchored E3 ligase variants. TCR specificity was achieved by direct fusion of an E3 domain to the CD3ζ transmembrane sequence. Jurkat and primary T cells stably expressing the ReceptorTAC constructs showed significantly reduced responses to TCR stimulation. We also used our ReceptorTAC technology to generate TCR-deficient, claudin18.2-specific CAR T cells, where the activity of the CAR was unaffected by the expression of the ReceptorTAC. These data indicate that our ReceptorTAC molecule can be used to generate allogeneic CAR T cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI